Background: Despite being one of the most commonly prescribed first line antiretroviral agents, the pharmacokinetics (PK) and pharmacodynamics of efavirenz (EFV) and its 8-hydroxy metabolite (8-OH-EFV), have not been robustlyrobustly evaluated in older HIV-infected patients. Moreover, 8-OH-EFV has been shown to be more neurotoxic in vitro than EFV. We sought to investigate relationships between neuropsychological performance (NP) with EFV and 8-OH-EFV PK in HIV-infected individuals >50 yo.
Methods: Cross sectional study of HIV-infected adults >50 yo, on EFV containing ART > 12 weeks. 12 h and 18 h post-dose plasma EFV and 8-OH-EFV were quantified via LC-MS-MS. CYP2B6 polymorphisms were investigated. NP battery assessed executive function, motor skills, verbal learning, memory, and speed of processing, CES-D depression scale and sleep quality index questionnaire were completed. Correlations of EFV and 8-OH-EFV plasma concentrations with NP performance, sleep, depression scores and CYP2B6 polymorphisms were assessed (Spearman’s correlation, and univariate logistic regression where appropriate).
Results: 30 participants 24 men, 6 women with mean age 57 yrs (50-68)were enrolled. Mean CD4 was 736/mm3 (range 145-2062); 26 participants had HIV RNA <20 c/mL and 4 < 100 c/mL. Median 12h and 18h EFV plasma concentrations were 1967 ng/mL (IQR 1476-2394) and 1676 ng/mL (IQR 1120-2062) respectively. Median 12hr and 18hr 8OH-EFV plasma concentrations were 378 ng/mL (IQR 223-589) and 384 ng/mL (IQR 216-621) respectively. EFV plasma concentrations did not correlate significantly with NP performance. Higher 8-OH-EFV plasma concentrations correlated with better learning (p=0.002), language (p=0.002) and total NPZ scores (p=0.005). Neither EFV nor 8OH-EFV plasma concentrations correlated with sleep disturbance or depression. The CYP2B6 516G>T polymorphism was associated with significantly higher concentrations of EFV at 12h and 18 h (p=0.02) but not NP function.
Conclusions: Better neurocognitive functioning was associated with higher 8-OH EFV but not EFV plasma concentrations. No correlation was observed with disturbed sleep or depression and exposure to EFV or the metabolite. These findings point to a need for greater understanding of the metabolic profile of EFV and 8-OH EFV in plasma and the CNS and relationships with antiviral effect and neurotoxicity.